Department of Prosthodontics, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou 510055, China.
Department of Oral Maxillofacial-Head and Neck Surgery, School of Stomatology, China Medical University, Oral Diseases Laboratory of Liaoning, Shenyang 110000, China.
Br J Oral Maxillofac Surg. 2022 Sep;60(7):868-876. doi: 10.1016/j.bjoms.2022.03.009. Epub 2022 Mar 29.
This study aimed to evaluate the clinical efficacy and histological outcomes of autogenous demineralised dentin matrix (ADDM) as bone graft material compared with Bio-Oss® in bone augmentation for the treatment of patients with oral bone deficits. Eight databases (PubMed, EMBASE, Cochrane Library, Science Direct, Scopus, Web of Science, CNKI, and WFPD) were searched for randomised controlled trials (RCT) performed from the date of inception of each database to July 2021. The Cochrane Collaboration's risk assessment tool was used to conduct the methodological quality assessment. Stata 15.0 software was used to perform data analysis. Seven RCTs including 220 patients were considered eligible for this study. No significant difference was found in the percentage of new bone formation (NBF) and implant stability quotient (ISQ). Patients who received ADDM grafting showed a significantly lower sinus height (SH) and percentage of residual graft material (RGM) compared with Bio-Oss® grafting. ADDM is as effective as Bio-Oss® in bone augmentation for oral bone defects.
本研究旨在评估脱矿牙本质基质（ADDM）作为骨移植材料与 Bio-Oss®相比在治疗口腔骨缺损患者的骨增量中的临床疗效和组织学结果。从每个数据库的创建日期到 2021 年 7 月，在 8 个数据库（PubMed、EMBASE、Cochrane Library、Science Direct、Scopus、Web of Science、CNKI 和 WFPD）中搜索了随机对照试验（RCT）。使用 Cochrane 协作的风险评估工具进行方法学质量评估。Stata 15.0 软件用于进行数据分析。共有 7 项 RCT 纳入了 220 名患者，符合本研究的纳入标准。新骨形成百分比（NBF）和种植体稳定性指数（ISQ）方面无显著差异。与 Bio-Oss®移植相比，接受 ADDM 移植的患者窦腔高度（SH）和残留移植物材料百分比（RGM）显著降低。ADDM 在口腔骨缺损的骨增量中与 Bio-Oss®同样有效。
